Ioannis Drositis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ioannis Drositis has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
A. Bertsias
1 shared publication- Achilleas Gikas
Internal Medicine Department, Infectious Diseases Unit, University Hospital of Heraklion, School of Medicine, University of Crete, 71500 Heraklion, Greece
1 shared publication - Christos Lionis
Clinic of Social and Family Medicine, School of Medicine, University of Crete, Heraklion, Greece
1 shared publication - Diamantis P. Kofteridis
Department of Internal Medicine University Hospital of Heraklion Heraklion Greece
1 shared publication - Dimitra Stafylaki
Department of Clinical Microbiology, University Hospital of Heraklion, 71110 Heraklion, Greece
1 shared publication E. Kouroumalis
1 shared publication
Latest Publications
- Open Access
- 22 June 2023
- Published by MDPI AG in Antibiotics
- Vol. 12 (7) , 1088
Impact of SARS-CoV-2 Preventive Measures against Healthcare-Associated Infections from Antibiotic-Resistant ESKAPEE Pathogens: A Two-Center, Natural Quasi-Experimental Study in Greece
The COVID-19 pandemic led to unprecedented stress on healthcare systems worldwide, forming settings of concern for increasing antimicrobial resistance. We investigated the impact of SARS-CoV-2 preventive measures against healthcare-associated infections (HAIs) from antibiotic-resistant bacteria in two tertiary-care hospitals. We compared infection rates between March 2019 and February 2020 (pre-intervention period) and March 2020 and February 2021 (COVID-19 intervention period) from drug-resistant ESKAPEE bacteria (methicillin-resistant Staphylococcus aureus; vancomycin-resistant Enterococci; carbapenem-resistant Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter species and Escherichia coli). Over 24 months, 586 drug-resistant ESKAPEE HAIs occurred in 439 patients (0.3% of 179,629 inpatients) with a mean age of 63 years, with 43% being treated in intensive care units (ICUs), and having a 45% inpatient mortality rate. Interrupted time series analysis revealed increasing infection rates before the intervention that were sharply interrupted by abrupt drops for most pathogens and henceforth remained stable in the ICUs but progressively increased in ordinary wards. In the ICUs, the pooled infection rate was 44% lower over the intervention period compared to the pre-intervention period (incidence rate ratio (IRR) 0.56, 95%CI 0.41–0.75, p < 0.001). Pooled infection rates in the wards were slightly higher over the COVID-19 period (IRR 1.12, 95%CI 0.87–1.45, p = 0.368). The findings confirmed the ancillary beneficial impact of the enhanced bundle of transmission-based precautions adopted against SARS-CoV-2 in rapidly constraining antimicrobial-resistant HAIs in two Greek hospitals.
- 22 June 2023
- Published by MDPI AG in Antibiotics
- Vol. 12 (7) , 1088
Open AccessImpact of SARS-CoV-2 Preventive Measures against Healthcare-Associated Infections from Antibiotic-Resistant ESKAPEE Pathogens: A Two-Center, Natural Quasi-Experimental Study in Greece
The COVID-19 pandemic led to unprecedented stress on healthcare systems worldwide, forming settings of concern for increasing antimicrobial resistance. We investigated the impact of SARS-CoV-2 preventive measures against healthcare-associated infections (HAIs) from antibiotic-resistant bacteria in two tertiary-care hospitals. We compared infection rates between March 2019 and February 2020 (pre-intervention period) and March 2020 and February 2021 (COVID-19 intervention period) from drug-resistant ESKAPEE bacteria (methicillin-resistant Staphylococcus aureus; vancomycin-resistant Enterococci; carbapenem-resistant Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter species and Escherichia coli). Over 24 months, 586 drug-resistant ESKAPEE HAIs occurred in 439 patients (0.3% of 179,629 inpatients) with a mean age of 63 years, with 43% being treated in intensive care units (ICUs), and having a 45% inpatient mortality rate. Interrupted time series analysis revealed increasing infection rates before the intervention that were sharply interrupted by abrupt drops for most pathogens and henceforth remained stable in the ICUs but progressively increased in ordinary wards. In the ICUs, the pooled infection rate was 44% lower over the intervention period compared to the pre-intervention period (incidence rate ratio (IRR) 0.56, 95%CI 0.41–0.75, p < 0.001). Pooled infection rates in the wards were slightly higher over the COVID-19 period (IRR 1.12, 95%CI 0.87–1.45, p = 0.368). The findings confirmed the ancillary beneficial impact of the enhanced bundle of transmission-based precautions adopted against SARS-CoV-2 in rapidly constraining antimicrobial-resistant HAIs in two Greek hospitals.
- 1 November 2019
- Vol. 24 (6) , 2579-2580
Interaction of brivudine with capecitabine: A case of serious toxicity
- 1 November 2019
- Vol. 24 (6) , 2579-2580
Interaction of brivudine with capecitabine: A case of serious toxicity
- 1 December 2013
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 24 (8) , 839-845
Epidemiology and molecular analysis of hepatitis A, B and C in a semi-urban and rural area of Crete
- 1 December 2013
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 24 (8) , 839-845
Epidemiology and molecular analysis of hepatitis A, B and C in a semi-urban and rural area of Crete